These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31408668)

  • 1. Participation in a Novel Trial Assessing Prophylactic Breast Irradiation: The Importance of Input From the Radiation Oncologist.
    Evron E; Goldberg H; Ben-David MA; Corn BW
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):792-794. PubMed ID: 31408668
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study.
    Jakub JW; Peled AW; Gray RJ; Greenup RA; Kiluk JV; Sacchini V; McLaughlin SA; Tchou JC; Vierkant RA; Degnim AC; Willey S
    JAMA Surg; 2018 Feb; 153(2):123-129. PubMed ID: 28903167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.
    Chiba A; Hoskin TL; Hallberg EJ; Cogswell JA; Heins CN; Couch FJ; Boughey JC
    Ann Surg Oncol; 2016 Oct; 23(10):3232-8. PubMed ID: 27338744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks.
    Boughey JC; Attai DJ; Chen SL; Cody HS; Dietz JR; Feldman SM; Greenberg CC; Kass RB; Landercasper J; Lemaine V; MacNeill F; Song DH; Staley AC; Wilke LG; Willey SC; Yao KA; Margenthaler JA
    Ann Surg Oncol; 2016 Oct; 23(10):3100-5. PubMed ID: 27469117
    [No Abstract]   [Full Text] [Related]  

  • 6. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing.
    Tercyak KP; Peshkin BN; Brogan BM; DeMarco T; Pennanen MF; Willey SC; Magnant CM; Rogers S; Isaacs C; Schwartz MD
    J Clin Oncol; 2007 Jan; 25(3):285-91. PubMed ID: 17159191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgeons' Perspectives of Contralateral Prophylactic Mastectomy.
    Bellavance E; Peppercorn J; Kronsberg S; Greenup R; Keune J; Lynch J; Collyar D; Magder L; Tilburt J; Hlubocky F; Yao K
    Ann Surg Oncol; 2016 Sep; 23(9):2779-87. PubMed ID: 27169770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations.
    Katz SJ; Kurian AW; Morrow M
    JAMA; 2015 Sep; 314(10):997-8. PubMed ID: 26203642
    [No Abstract]   [Full Text] [Related]  

  • 9. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
    Gronwald J; Tung N; Foulkes WD; Offit K; Gershoni R; Daly M; Kim-Sing C; Olsson H; Ainsworth P; Eisen A; Saal H; Friedman E; Olopade O; Osborne M; Weitzel J; Lynch H; Ghadirian P; Lubinski J; Sun P; Narod SA;
    Int J Cancer; 2006 May; 118(9):2281-4. PubMed ID: 16331614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contralateral risk-reducing mastectomy in young women.
    Merck B
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():29-32. PubMed ID: 20711671
    [No Abstract]   [Full Text] [Related]  

  • 11. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.
    Gaffney DK; Hemmersmeier J; Holden J; Marshall J; Smith LM; Avizonis V; Tran T; Neuhausen SL
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):539-46. PubMed ID: 11173152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy.
    McQuirter M; Castiglia LL; Loiselle CG; Wong N
    Oncol Nurs Forum; 2010 May; 37(3):313-20. PubMed ID: 20439215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rectal Cancer: The Radiation Oncologist: The Great Watchmaker.
    Maingon P; Huguet F
    Semin Radiat Oncol; 2016 Jul; 26(3):173-5. PubMed ID: 27238467
    [No Abstract]   [Full Text] [Related]  

  • 15. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
    Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
    Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contralateral Prophylactic Mastectomy for Women with T4 Locally Advanced Breast Cancer.
    Murphy BL; Hoskin TL; Boughey JC; Degnim AC; Glazebrook KN; Hieken TJ
    Ann Surg Oncol; 2016 Oct; 23(10):3365-70. PubMed ID: 27364506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
    Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
    Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of risk-reducing surgery with cancer risks and mortality in BRCA mutation carriers.
    Heemskerk-Gerritsen BA; Kriege M; Seynaeve C
    JAMA; 2010 Dec; 304(24):2695; author reply 2695-6. PubMed ID: 21177502
    [No Abstract]   [Full Text] [Related]  

  • 19. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women.
    Bresser PJ; Seynaeve C; Van Gool AR; Brekelmans CT; Meijers-Heijboer H; van Geel AN; Menke-Pluijmers MB; Duivenvoorden HJ; Klijn JG; Tibben A
    Plast Reconstr Surg; 2006 May; 117(6):1675-82; discussion 1683-4. PubMed ID: 16651934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
    Menes TS; Terry MB; Goldgar D; Andrulis IL; Knight JA; John EM; Liao Y; Southey M; Miron A; Chung W; Buys SS
    Breast Cancer Res Treat; 2015 Jun; 151(3):653-60. PubMed ID: 25975955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.